551 related articles for article (PubMed ID: 7655033)
1. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients.
Kolb HJ; Schattenberg A; Goldman JM; Hertenstein B; Jacobsen N; Arcese W; Ljungman P; Ferrant A; Verdonck L; Niederwieser D; van Rhee F; Mittermueller J; de Witte T; Holler E; Ansari H;
Blood; 1995 Sep; 86(5):2041-50. PubMed ID: 7655033
[TBL] [Abstract][Full Text] [Related]
2. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
3. Adoptive immunotherapy with donor lymphocyte transfusions.
Kolb HJ; Holler E
Curr Opin Oncol; 1997 Mar; 9(2):139-45. PubMed ID: 9161791
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
Naparstek E; Nagler A; Or R; Kapelushnik J; Slavin S
Clin Transpl; 1996; ():281-90. PubMed ID: 9286578
[TBL] [Abstract][Full Text] [Related]
5. Use of unrelated marrow grafts compensates for reduced graft-versus-leukemia reactivity after T-cell-depleted allogeneic marrow transplantation for chronic myelogenous leukemia.
Hessner MJ; Endean DJ; Casper JT; Horowitz MM; Keever-Taylor CA; Roth M; Flomenberg N; Drobyski WR
Blood; 1995 Nov; 86(10):3987-96. PubMed ID: 7579370
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes.
Slavin S; Naparstek E; Nagler A; Ackerstein A; Kapelushnik J; Or R
Exp Hematol; 1995 Dec; 23(14):1553-62. PubMed ID: 8542946
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
[TBL] [Abstract][Full Text] [Related]
8. T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation.
Drobyski WR; Hessner MJ; Klein JP; Kabler-Babbitt C; Vesole DH; Margolis DA; Keever-Taylor CA
Blood; 1999 Jul; 94(2):434-41. PubMed ID: 10397710
[TBL] [Abstract][Full Text] [Related]
9. Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant.
Alyea EP; Soiffer RJ; Canning C; Neuberg D; Schlossman R; Pickett C; Collins H; Wang Y; Anderson KC; Ritz J
Blood; 1998 May; 91(10):3671-80. PubMed ID: 9573003
[TBL] [Abstract][Full Text] [Related]
10. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation.
Giralt S; Hester J; Huh Y; Hirsch-Ginsberg C; Rondón G; Seong D; Lee M; Gajewski J; Van Besien K; Khouri I; Mehra R; Przepiorka D; Körbling M; Talpaz M; Kantarjian H; Fischer H; Deisseroth A; Champlin R
Blood; 1995 Dec; 86(11):4337-43. PubMed ID: 7492795
[TBL] [Abstract][Full Text] [Related]
11. Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: lower incidence of acute graft-versus-host disease and improved outcome.
Shiobara S; Nakao S; Ueda M; Yamazaki H; Takahashi S; Asano S; Yabe H; Kato S; Imoto S; Maruta A; Yoshida T; Gondo H; Morishima Y; Kodera Y
Bone Marrow Transplant; 2000 Oct; 26(7):769-74. PubMed ID: 11042659
[TBL] [Abstract][Full Text] [Related]
12. Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: indications and dose escalation.
Shiobara S; Nakao S; Ueda M; Yamazaki H; Takahashi S; Asano S; Yabe H; Kato S; Imoto S; Maruta A; Yoshida T; Gondo H; Morishima Y; Kodera Y
Ther Apher; 2001 Feb; 5(1):40-5. PubMed ID: 11258609
[TBL] [Abstract][Full Text] [Related]
13. Induction of graft-versus-host disease as immunotherapy of leukemia relapsing after allogeneic transplantation: single-center experience of 32 adult patients.
Mehta J; Powles R; Kulkarni S; Treleaven J; Singhal S
Bone Marrow Transplant; 1997 Jul; 20(2):129-35. PubMed ID: 9244416
[TBL] [Abstract][Full Text] [Related]
14. Donor leukocyte transfusions for treatment of leukemic relapse after bone marrow transplantation. EBMT Immunology and Chronic Leukemia Working Parties.
Kolb HJ
Vox Sang; 1998; 74 Suppl 2():321-9. PubMed ID: 9704463
[TBL] [Abstract][Full Text] [Related]
15. Adoptive immunotherapy with donor mononuclear cell infusions to treat relapse of acute leukemia or myelodysplasia after allogeneic bone marrow transplantation.
Porter DL; Roth MS; Lee SJ; McGarigle C; Ferrara JL; Antin JH
Bone Marrow Transplant; 1996 Nov; 18(5):975-80. PubMed ID: 8932854
[TBL] [Abstract][Full Text] [Related]
16. Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells.
Verdonck LF; Petersen EJ; Lokhorst HM; Nieuwenhuis HK; Dekker AW; Tilanus MG; de Weger RA
Bone Marrow Transplant; 1998 Dec; 22(11):1057-63. PubMed ID: 9877267
[TBL] [Abstract][Full Text] [Related]
17. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia.
Porter DL; Roth MS; McGarigle C; Ferrara JL; Antin JH
N Engl J Med; 1994 Jan; 330(2):100-6. PubMed ID: 8259165
[TBL] [Abstract][Full Text] [Related]
18. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease.
Mackinnon S; Papadopoulos EB; Carabasi MH; Reich L; Collins NH; Boulad F; Castro-Malaspina H; Childs BH; Gillio AP; Kernan NA
Blood; 1995 Aug; 86(4):1261-8. PubMed ID: 7632930
[TBL] [Abstract][Full Text] [Related]
19. [Therapeutic effect of donor leukocyte transfusion in relapsing marrow transplants in Japan].
Shiobara S; Takahasi S; Yabe H; Maruta I; Kodera Y
Rinsho Ketsueki; 1997 Nov; 38(11):1162-9. PubMed ID: 9423332
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic bone marrow transplantation from unrelated donors using in vivo anti-T-cell globulin.
Finke J; Bertz H; Schmoor C; Veelken H; Behringer D; Wäsch R; Kunzmann R; Heidecker L; Lang H; Meyer-König U; Mertelsmann R
Br J Haematol; 2000 Oct; 111(1):303-13. PubMed ID: 11091217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
